메뉴 건너뛰기




Volumn 22, Issue 7, 2014, Pages 2005-2032

Synthetic approaches to the 2012 new drugs

Author keywords

Medicine; New chemical entities; New drug molecules; Synthesis; Therapeutic agents

Indexed keywords

A 77 1726; ACLIDINIUM BROMIDE; ALLISARTAN ISOPROXIL; ANAGLIPTIN; APPEBB; AXITINIB; AZILSARTAN; AZILVA; BEDAQUILINE; BESKOA; BOSUTINIB; BRETARIS GENUAI; CABOZANTINIB; CARERAM; CARFILZOMIB; DAPAGLIFLOZIN; EDISTRIDE; EMPLICITI; ENZALUTAMIDE; HENGYANG; HOMOHARRINGTONINE; IGURATIMOD; IMRECOXIB; INGENOL MEBUTATE; IREMOD; IVACAFTOR; LORCASERIN; NEW DRUG; PASIREOTIDE; PERAMPANEL; PIXANTRONE; PONATINIB; RADOTINIB; REGORAFENIB; SUINY; SUPECT; TAFAMIDIS; TENELIA; TENELIGLIPTIN; TERIFLUNOMIDE; TOFACITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISMODEGIB; DRUG;

EID: 84897421694     PISSN: 09680896     EISSN: 14643391     Source Type: Journal    
DOI: 10.1016/j.bmc.2014.02.017     Document Type: Review
Times cited : (46)

References (231)
  • 21
    • 84897407275 scopus 로고    scopus 로고
    • WO Patent 2007/095789 A1
    • Guo, J. H.; An, D. WO Patent 2007/095789 A1, 2007.
    • (2007)
    • Guo, J.H.1    An, D.2
  • 22
    • 84897459534 scopus 로고    scopus 로고
    • CN Patent 101367795 B
    • An, D.; Guo, J. H. CN Patent 101367795 B, 2012.
    • (2012)
    • An, D.1    Guo, J.H.2
  • 41
    • 84897390763 scopus 로고    scopus 로고
    • US Patent 5583141 A
    • Naka, T.; Inada, Y. US Patent 5583141 A, 1996.
    • (1996)
    • Naka, T.1    Inada, Y.2
  • 42
    • 84897446712 scopus 로고    scopus 로고
    • EP Patent 0520423 A2
    • Naka, T.; Inada, Y. EP Patent 0520423 A2, 2003.
    • (2003)
    • Naka, T.1    Inada, Y.2
  • 43
    • 84897464949 scopus 로고    scopus 로고
    • Raídl, S.; Cernyí, J.; Stach, J.; Gablíkovaí
    • Raídl, S.; Cernyí, J.; Stach, J.; Gablíkovaí, Z. Org. Process Res. Dev. 2013, 17, 77.
    • (2013) Z. Org. Process Res. Dev. , vol.17 , pp. 77
  • 65
    • 84897427028 scopus 로고    scopus 로고
    • WO Patent 2012/109510 A1
    • Wilson, J. A. WO Patent 2012/109510 A1, 2012.
    • (2012)
    • Wilson, J.A.1
  • 81
    • 84897422362 scopus 로고    scopus 로고
    • WO Patent 2013/087004 A1
    • Chen, Y. WO Patent 2013/087004 A1, 2013.
    • (2013)
    • Chen, Y.1
  • 83
    • 84897400880 scopus 로고    scopus 로고
    • Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan, 2012, [Access Date: 2012-July-29]
    • Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan, 2012, http://www.eisai.com/news/news201239.html, [Access Date: 2012-July-29].
  • 92
    • 84897430432 scopus 로고    scopus 로고
    • US Patent 2004/0029951 A1
    • Guo, Z.; Cheng, G.; Chu, F. US Patent 2004/0029951 A1, 2004.
    • (2004)
    • Guo, Z.1    Cheng, G.2    Chu, F.3
  • 116
    • 84897429003 scopus 로고    scopus 로고
    • FDA approves Kalydeco to treat rare form of cystic fibrosis, [Access Date: 2012-Jan-31]
    • FDA approves Kalydeco to treat rare form of cystic fibrosis, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289633.htm, [Access Date: 2012-Jan-31].
  • 119
  • 122
    • 84897380425 scopus 로고    scopus 로고
    • WO Patent 2007/079139 A2
    • Hurter, P. WO Patent 2007/079139 A2, 2007.
    • (2007)
    • Hurter, P.1
  • 123
    • 84897417986 scopus 로고    scopus 로고
    • WO Patent 2007/134279 A2
    • Young, C. R.; Rowe, C. W. WO Patent 2007/134279 A2, 2007.
    • (2007)
    • Young, C.R.1    Rowe, C.W.2
  • 124
    • 84897436813 scopus 로고    scopus 로고
    • US Patent 2008/0090864 A1
    • Young, C. R.; Rowe, C. W. US Patent 2008/0090864 A1, 2008.
    • (2008)
    • Young, C.R.1    Rowe, C.W.2
  • 132
    • 84897377974 scopus 로고    scopus 로고
    • WO Patent 2012/158885 A1
    • Morgan, A. J. WO Patent 2012/158885 A1, 2012.
    • (2012)
    • Morgan, A.J.1
  • 133
    • 84897465273 scopus 로고    scopus 로고
    • WO Patent 2013/067410 A1
    • Van Goor, F. F. WO Patent 2013/067410 A1, 2013.
    • (2013)
    • Van Goor, F.F.1
  • 134
  • 149
    • 84897452572 scopus 로고    scopus 로고
    • CN Patent 1493572 A
    • Li, G. P.; Wu, X. P. CN Patent 1493572 A, 2004.
    • (2004)
    • Li, G.P.1    Wu, X.P.2
  • 150
    • 84897413487 scopus 로고    scopus 로고
    • US Patent 2010/0240887 A1
    • Liu, Y. US Patent 2010/0240887 A1, 2010.
    • (2010)
    • Liu, Y.1
  • 163
    • 84897408111 scopus 로고    scopus 로고
    • [Access Date: 2012-May-31]
    • Pixuvri, 2012, http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002055/human-med-001549.jsp&mid= WC0b01ac058001d124, [Access Date: 2012-May-31].
    • (2012) Pixuvri
  • 172
    • 84897402317 scopus 로고
    • EP Patent 503537 A1
    • Krapcho, P. A. EP Patent 503537 A1, 1992.
    • (1992)
    • Krapcho, P.A.1
  • 181
    • 84897407870 scopus 로고    scopus 로고
    • Droppert, P. In Biotech Strategy Blog: http://biotechstrategyblog.com/ 2012/01/radotinib-approved-in-south-korea-for-cml.html/, 2012.
    • (2012) Biotech Strategy Blog
    • Droppert, P.1
  • 189
    • 84897443596 scopus 로고    scopus 로고
    • Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST, [Access Date: 2013-Feb-25]
    • Bayer's Stivarga® (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Locally Advanced, Unresectable or Metastatic GIST, http://www.onyx.com/view.cfm/662/bayers-stivarga-regorafenib-tablets-approved- by-us-fda-for-treatment-of-patients-with-locally-advanced-unresectable-or- metastatic-gist, [Access Date: 2013-Feb-25].
  • 201
    • 84897442404 scopus 로고    scopus 로고
    • WO Patent 2004/056315 A2
    • Kelly, J. W.; Sekijima, Y. WO Patent 2004/056315 A2, 2004.
    • (2004)
    • Kelly, J.W.1    Sekijima, Y.2
  • 206
    • 84897391243 scopus 로고    scopus 로고
    • WO Patent 2012018704 A1
    • Rocklin, R. WO Patent 2012018704 A1, 2012.
    • (2012)
    • Rocklin, R.1
  • 213
    • 84897389541 scopus 로고    scopus 로고
    • CN Patent 102786437 A
    • Chen, G.; Sun, L. CN Patent 102786437 A, 2012.
    • (2012)
    • Chen, G.1    Sun, L.2
  • 221
    • 84897415532 scopus 로고    scopus 로고
    • WO Patent 2003/048162 A1
    • Flanagan, M. E.; Li, Z. J. WO Patent 2003/048162 A1, 2003.
    • (2003)
    • Flanagan, M.E.1    Li, Z.J.2
  • 225
    • 84897417066 scopus 로고    scopus 로고
    • FDA approves new treatment for most common type of skin cancer, [Access Date: 2012-Jan-30]
    • FDA approves new treatment for most common type of skin cancer, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm289545.htm, [Access Date: 2012-Jan-30].


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.